Cancer Research and Treatment

Original Articles

Lung and Thoracic cancer

miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37: Mi Seong Kim, So Hui Kim, Sei Hoon Yang, Min Seuk Kim; Cancer Res Treat. 2022;54(2):445-457. Published online August 3, 2021; DOI: https://doi.org/10.4143/crt.2021.622

Purpose
With the identification of epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) cells, EGFR–tyrosine kinase inhibitors (TKIs) are being used widely as the first-line of treatment in NSCLC. These inhibitors block auto-phosphorylation of activated EGFR by competing with ATP binding and mediate EGFR degradation independent of exogenous epidermal growth factor, which is associated with the mutation variants of EGFR. However, the precise mechanisms underlying the TKI-mediated EGFR degradation are still unclear.
Materials and Methods
To examine the physiological roles of miR-4487 and ubiquitin-specific peptidase 37 (USP37) in gefitinib-mediated EGFR degradation in NSCLC cells, multiple NSCLC cell lines were applied. The level of EGFR expression, apoptosis marker and autophagic flux were determined by western blot. Expression level of miR-4487 and cell cycle arrest was analyzed by TaqMan assay and flow cytometry respectively.
Results
We found that gefitinib mediates EGFR degradation under normal culture conditions, and is dependent on autophagic flux and the mutation variants of EGFR. Gefitinib reduced expression levels of USP37, which mediated EGFR degradation similar to gefitinib. Our results also showed a gefitinib-mediated increase in endogenous miR-4487 level and presented evidence for the direct targeting of USP37 by miR-4487, resulting in the sequential enhancement of ubiquitination, autophagy, and EGFR degradation. Thus, the depletion of USP37 and overexpression of miR-4487 led to an increase in gefitinib-mediated apoptotic cell death.
Conclusion
These data suggest that miR-4487 is a potential target for treating NSCLC, and miR-4487/USP37-regulated EGFR degradation is a determinant for developing gefitinib resistance.

Citations

Citations to this article as recorded by

Epigenetic code underlying EGFR-TKI resistance in non-small cell lung cancer: Elucidation of mechanisms and perspectives on therapeutic strategies
XiaoYu Yao, Chundi Gao, Changgang Sun, Zhe-Sheng Chen, Jing Zhuang
Drug Discovery Today.2025; 30(3): 104321. CrossRef
Deubiquitination of epidermal growth factor receptor by ubiquitin-specific peptidase 54 enhances drug sensitivity to gefitinib in gefitinib-resistant non-small cell lung cancer cells
Mi Seong Kim, Min Seuk Kim, Chien-Feng Li
PLOS ONE.2025; 20(4): e0320668. CrossRef
MicroRNAs as Sensitizers of Tyrosine Kinase Inhibitor Resistance in Cancer: Small Molecule Partnerships
Alma D. Campos-Parra, David Sánchez-Marín, Víctor Acevedo-Sánchez
Pharmaceuticals.2025; 18(4): 492. CrossRef
Mechanistic Insights and Therapeutic Potentials of Ubiquitin‐Proteasome System in Non‐Small Cell Lung Cancer
Guangyao Zhou, Jiaxiong Tan, Pengpeng Zhang, Zhaokai Zhou, Lianmin Zhang, Zhenfa Zhang
Cell Proliferation.2025;[Epub] CrossRef
Exploring the potential function of high expression of ANAPC1 in regulating ubiquitination in hepatocellular carcinoma
Yu-Xing Tang, Wei-Zi Wu, Sheng-Sheng Zhou, Da-Tong Zeng, Guang-Cai Zheng, Rong-Quan He, Di-Yuan Qin, Wan-Ying Huang, Ji-Tian Chen, Yi-Wu Dang, Yu-Lu Tang, Bang-Teng Chi, Yan-Ting Zhan, Gang Chen
World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
The significance of the crosstalk between ubiquitination or deubiquitination and ncRNAs in non-small cell lung cancer
Yiyang Sun, Ping He, Li Li, Xue Ding
Frontiers in Oncology.2023;[Epub] CrossRef
Lung adenocarcinoma cell-derived exosomes promote M2 macrophage polarization through transmission of miR-3153 to activate the JNK signaling pathway
L Xu, L Wang, R Yang, T Li, X Zhu
Human Molecular Genetics.2023; 32(13): 2162. CrossRef
The potential role of miRNAs in the pathogenesis of salivary gland cancer – A Focus on signaling pathways interplay
Ahmed I. Abulsoud, Shereen Saeid Elshaer, Ahmed A. El-Husseiny, Doaa Fathi, Nourhan M. Abdelmaksoud, Sherif S. Abdel Mageed, Aya Salman, Mohamed Bakr Zaki, Hesham A. El-Mahdy, Ahmed Ismail, Elsayed G.E. Elsakka, Mai A. Abd-Elmawla, Hussein M. El-Husseiny,
Pathology - Research and Practice.2023; 247: 154584. CrossRef

7,878 View
204 Download
10 Web of Science
8 Crossref

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy: Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo; Cancer Res Treat. 2019;51(1):169-177. Published online April 5, 2018; DOI: https://doi.org/10.4143/crt.2017.491

Abstract PDF PubReader ePub

Purpose
Despite the successful use of tyrosine kinase inhibitors (TKIs) in cancer patients, their effect on herpes zoster development has not been studied. The aim of this study was to evaluate and compare the effects of epidermal growth factor receptor (EGFR) TKI and cytotoxic chemotherapy on the risk of herpes zoster development in non-small cell lung cancer (NSCLC) patients.
Materials and Methods
We conducted a medical review of all eligible NSCLC patients in Seoul National University hospital between 2002 and 2015. We classified patients based on whether they previously underwent EGFR TKI therapy into either the TKI group or the cytotoxic group. We compared the incidence rates of herpes zoster during TKI therapy and cytotoxic chemotherapy. Additionally, the longitudinal risk of herpes zoster from TKIs was analyzed using the incidence rate ratio (IRR) of the TKI group to the cytotoxic group and the log-rank test of the Kaplan-Meier method.
Results
Of the 2,981 NSCLC patients, 54 patients (1.54%) developed herpes zoster. In the TKI group (2,002 patients), the IRR of herpes zoster during TKI therapy compared to that during cytotoxic chemotherapy was 1.05 (95% confidence interval [CI], 0.53 to 2.09). The IRR of the TKI group compared to the cytotoxic group was 1.33 (95% CI, 0.64 to 2.76). The Kaplan-Meier cumulative risk of both groups was not significantly different.
Conclusion
Our results show that the incidence rate of herpes zoster in the TKI group was not statistically different from the incidence in the cytotoxic group during and after chemotherapy in NSCLC patients.

Citations

Citations to this article as recorded by

The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects
Bei Cao, Tingting Ma, Yuqiang Zhang, Lei Huang, Hui Lin, Huanhuan Jiang, Yu Zhao, Yan Geng, Yuanxun Yang, Sumin Cao, Juan Li
Investigational New Drugs.2024; 42(3): 289. CrossRef
Reactivation of Varicella-Zoster Virus in Patients with Lung Cancer Receiving Immune Checkpoint Inhibitors: Retrospective Nationwide Population-Based Cohort Study from South Korea
Jiyun Jung, Seong-Yeon Park, Jae-Yoon Park, Dalyong Kim, Kyoungmin Lee, Sungim Choi
Cancers.2024; 16(8): 1499. CrossRef
Herpes Zoster in Patients with Lung Cancer Treated with PD-1/PD-L1 Antibodies
Yoshiaki Nagai, Masafumi Sata, Hiromitsu Ohta, Tsugitoshi Onuki, Tatsuya Saito, Ayumi Uchiyama, Ayako Kurosaki, Naoko Yoshizumi, Ayako Takigami, Shoko Nakazawa, Masayuki Nakayama, Hironori Yamaguchi, Koichi Hagiwara
Immunotherapy.2022; 14(15): 1211. CrossRef
Generalized herpes zoster and cutaneous metastasis during chemotherapy for non‐small cell lung cancer: A case report
Naoya Yasokawa, Yuri Yasuda, Houhi Chin, Koji Kurose, Yumi Aoyama, Toru Oga
Thoracic Cancer.2021; 12(1): 117. CrossRef
The risk of herpes zoster among patients with ankylosing spondylitis: A population‐based cohort study in Taiwan
Shuya Wang, James Cheng‐Chung Wei, Jing‐Yang Huang, Wuu‐Tsun Perng, Zhiyi Zhang
International Journal of Rheumatic Diseases.2020; 23(2): 181. CrossRef

9,070 View
242 Download
6 Web of Science
5 Crossref

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients: Seung-Hoon Beom, Dong-Wan Kim, Sung Hoon Sim, Bhumsuk Keam, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo; Cancer Res Treat. 2016;48(1):88-97. Published online March 3, 2015; DOI: https://doi.org/10.4143/crt.2014.201

Abstract PDF PubReader ePub

Purpose
Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the incidence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carcinoma patients treated with gefitinib. Materials and Methods A retrospective cohort study was performed in non-small cell lung cancer (NSCLC) patients who started gefitinib treatment at Seoul National University Hospital from January 2002 through December 2011. Patients who developed new abnormal radiologic findings with respiratory symptoms after gefitinib treatment were defined as having possible adverse pulmonary reactions. The patients’ medical records were reviewed independently by investigators to identify the causes of pulmonary toxicities. Results Among the 1,114 patients evaluated, 128 patients (11.5%) developed pulmonary adverse reactions after taking gefitinib. An infectious complication occurred in 98 patients (8.8%) and 15 patients (1.3%) developed ILD. Nine of the 15 patients (60.0%) with gefitinib-induced ILD experienced a fatal clinical course that met either the Common Terminology Criteria for Adverse Events grade 4 (n=3) or grade 5 (n=6). In the multivariate analysis, a lower serum albumin level (≤ 3.0 g/dL) at baseline was significantly associated with the development of gefitinib-induced ILD (odds ratio, 3.91; 95% confidence interval, 1.20 to 12.71). Conclusion The incidence of gefitinib-induced ILD in Korean NSCLC patients was similar to that reported worldwide, but lower than values reported for Japanese population. ILD was usually a lifethreatening adverse effect of gefitinib, and the development of ILD was significantly associated with a lower baseline serum albumin level.

Citations

Citations to this article as recorded by

Incidence and risk of drug-induced interstitial lung disease associated with anti-neoplastic drugs
Il-Hyung Hwang, Seung Hyeun Lee, Hankil Lee
Expert Opinion on Drug Safety.2025; : 1. CrossRef
Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis
Yosuke Fukuda, Yoshitaka Uchida, Koichi Ando, Ryo Manabe, Akihiko Tanaka, Hironori Sagara
Respiratory Investigation.2024; 62(3): 481. CrossRef
Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats
Wael A. Alanazi, Hussain N. Alhamami, Ali A. Alshamrani, Faleh Alqahtani, Abdulrahman Alshammari, Khalid Alhazzani, Mohammed Alswayyed
Saudi Journal of Biological Sciences.2023; 30(2): 103522. CrossRef
Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan
Qingqing Hu, Kuan-Chih Huang, Choo Hua Goh, Yumi Tsuchiya, Yanfang Liu, Hong Qiu
Scientific Reports.2023;[Epub] CrossRef
Sensorineural hearing loss induced by gefitinib: A CARE-compliant case report and literature reviews
Bao-chen Zhu, Wen-hua Yang, Mao Huang, Jin-gui Wang, Yan Liang, Zhen-zhen Lei, Sha-sha Zhang, Ying Wang, Xiao-di Sun, Ying Gong, Chun-miao Xue, Guo-dong Hua
Medicine.2023; 102(45): e36010. CrossRef
Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism
Alessio Basolo, Antonio Matrone, Rossella Elisei, Ferruccio Santini
Seminars in Cancer Biology.2022; 79: 197. CrossRef
Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience
Min-Young Lee, Seug Yun Yoon, Kyoung Ha Kim, Namsu Lee, Ha Youn Kim, Jung Hwa Hwang, Jong-Ho Won
The Korean Journal of Internal Medicine.2021; 36(3): 689. CrossRef
Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China
Xie Xiaohong, Wang Liqiang, Li Na, Lin Xinqing, Qin Yinyin, Liu Ming, Ouyang Ming, Han Qian, Luo Qun, Li Shiyue, Li Chunyan, Wang Xiaoqian, Yang Shuanying, Huang Wei, Liu Mei, Wang Ping, Zhou Chengzhi
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis
Tomonori Hirashima, Miyako Satouchi, Toyoaki Hida, Makoto Nishio, Terufumi Kato, Hiroshi Sakai, Fumio Imamura, Katsuyuki Kiura, Isamu Okamoto, Kazuo Kasahara, Hirohiko Uchida, Sarah L. Vowler, Tetsuya Mitsudomi
Cancer Science.2019; 110(9): 2884. CrossRef
Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective
Shigeki Saito, Joseph A. Lasky, Koichi Hagiwara, Yasuhiro Kondoh
Respiratory Investigation.2018; 56(5): 375. CrossRef
Personalized chemotherapy of lung cancer: What the radiologist should know
G.R. Ferretti, E. Reymond, A. Delouche, L. Sakhri, A. Jankowski, D. Moro-Sibilot, S. Lantuejoul, A.C. Toffart
Diagnostic and Interventional Imaging.2016; 97(3): 287. CrossRef
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Rashmi R. Shah
Drug Safety.2016; 39(11): 1073. CrossRef
Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer
Namhun Lee, Kangwook Lee, Yoon-sik Kim, Chang-Gue Son, Jung-Hyo Cho, Hwa-Seung Yoo, Jonghoon Lee, Juyoung Ryu
Journal of Pharmacopuncture.2016; 19(3): 259. CrossRef
Imagerie du suivi post-thérapeutique des traitements personnalisés systémiques du cancer bronchique
G. Ferretti, E. Reymond, J. Cohen, A. Jankowski, M. Giaj-Levra, A.C. Toffart, D. Moro-Sibilot
Revue des Maladies Respiratoires Actualités.2016; 8(5): 325. CrossRef

15,522 View
134 Download
15 Web of Science
14 Crossref

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer: Young Saing Kim, Eun Kyung Cho, Hyun Sun Woo, Junshik Hong, Hee Kyung Ahn, Inkeun Park, Sun Jin Sym, Sun Young Kyung, Shin Myung Kang, Jeong-Woong Park, Sung Hwan Jeong, Jinny Park, Jae Hoon Lee, Dong Bok Shin; Cancer Res Treat. 2016;48(1):80-87. Published online March 2, 2015; DOI: https://doi.org/10.4143/crt.2014.307

Abstract PDF PubReader ePub

Purpose
This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. Materials and Methods Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m² of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. The primary end point was progression-free survival (PFS) at 6 months.
Results
A total of 95 patients were enrolled (47 for pemetrexed and 48 for gefitinib). Most patients were male (72%) and current/ex-smokers (69%), and 80% had non-squamous cell carcinoma. The epidermal growth factor receptor (EGFR) mutation status was determined in 38 patients (40%); one patient per each arm was positive for EGFRmutation. The 6-month PFS rates were 22% and 15% for pemetrexed and gefitinib, respectively (p=0.35). Both arms showed an identical median PFS of 2.0 months and a median overall survival (OS) of 8.5 months. In EGFR wild-type patients, higher response rate (RR) and longer PFS as well as OS were achieved via pemetrexed compared with gefitinib, although there were no significant differences (RR: 39% vs. 9%, p=0.07; median PFS: 6.6 months vs. 3.1 months, p=0.45; median OS: 29.6 months vs. 12.9 months, p=0.62). Toxicities were mild in both treatment arms. Frequently reported toxicities were anemia and fatigue for pemetrexed, and skin rash and anorexia for gefitinib. Conclusion Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. However, pemetrexed is considered more effective than gefitinib for EGFR wild-type patients.

Citations

Citations to this article as recorded by

Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database
Jing Shi, Xinya Liu, Mengjiao Gao, Jian Yu, Ting Chai, Yun Jiang, Jiawei Li, Yuanming Zhang, Li Wu
Frontiers in Pharmacology.2025;[Epub] CrossRef
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer
Himani Aggarwal, Kerigo Ndirangu, Katherine B Winfree, Catherine Elizabeth Muehlenbein, Emily Zhu, Vanita Tongbram, Howard Thom
Journal of Comparative Effectiveness Research.2023;[Epub] CrossRef
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
Yi Zhao, Bo Cheng, Zisheng Chen, Jianfu Li, Hengrui Liang, Ying Chen, Feng Zhu, Caichen Li, Ke Xu, Shan Xiong, Weixiang Lu, Zhuxing Chen, Ran Zhong, Shen Zhao, Zhanhong Xie, Jun Liu, Wenhua Liang, Jianxing He
Critical Reviews in Oncology/Hematology.2021; 160: 103305. CrossRef
Efficacy and Safety of Pemetrexed and Gefitinib in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis
Zhihao Zhang, Xiyong Wang, Huaiqing Xiao, Dongqiang Wu, Dongliang Zhang, Qun Yu, Linna Yuan, Tao Huang
Computational and Mathematical Methods in Medicine.2021; 2021: 1. CrossRef
A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC
Xiaoxin Lu, Shengshu Li, Weizong Chen, Dongyang Zheng, Yuzhu Li, Fang Li
Medicine.2020; 99(29): e21170. CrossRef
Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
Huiyu Wang, Zunjing Zhang, Feng Liu, Miaoying Zhou, Handi Lv
Pteridines.2019; 30(1): 171. CrossRef
Gefitinib for advanced non-small cell lung cancer
Esther HA Sim, Ian A Yang, Richard Wood-Baker, Rayleen V Bowman, Kwun M Fong
Cochrane Database of Systematic Reviews.2018;[Epub] CrossRef
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients
Chong Hyun Suh, Hye Sun Park, Kyung Won Kim, Junhee Pyo, Hiroto Hatabu, Mizuki Nishino
Lung Cancer.2018; 123: 60. CrossRef
Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
Jens Köhler
Frontiers in Medicine.2017;[Epub] CrossRef

13,702 View
127 Download
16 Web of Science
9 Crossref

How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution: Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo; Cancer Res Treat. 2013;45(3):178-185. Published online September 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.3.178

Abstract PDF PubReader ePub

PURPOSE
Gefitinib was introduced in 2002 for treatment of non-small cell lung cancer (NSCLC); however, it is not clear whether its use in daily practice has changed the outcome of patients. The purpose of this study is to evaluate the question of how molecular understanding regarding gefitinib and epidermal growth factor receptor (EGFR) mutation affect the prescribing patterns and clinical outcomes of treatment with gefitinib in NSCLC, in a real practical field.
MATERIALS AND METHODS
We conducted a retrospective analysis of the consecutive database of NSCLC patients who were treated with gefitinib at Seoul National University Hospital between January 2002 and December 2011. Prescribing patterns and clinical outcomes were analyzed by year.
RESULTS
A total of 1,115 NSCLC patients, who received gefitinib at recurred or metastatic setting, were included in this study. Proportion of patients receiving gefitinib, for the first line, showed a gradual increase, from 5.2% in 2002-2003 to 30.6% in 2010-2011. Proportion of patients who underwent EGFR mutation testing showed a rapid increase, from 0.6% in 2004-2005 to 73.5% in 2010-2011. The response rate also showed a gradual increase, from 17.2% in 2002-2003 to 57.1% in 2010-2011 (p<0.001). The median progression-free survival of gefitinib was increased with statistical significance from 2.8 months in 2002-2003 to 9.1 months in 2010-2011 (p<0.001).
CONCLUSION
We demonstrated that molecular understanding and practical use of EGFR mutation testing have resulted in a change in the prescription patterns of gefitinib. Use of an enrichment strategy can lead to improvement in the efficacy of gefitinib in real practice.

Citations

Citations to this article as recorded by

Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review
Aye Myat Thi, Sandar Tin Tin, Mark McKeage, J. Mark Elwood
Targeted Oncology.2020; 15(3): 279. CrossRef
The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo
Cancer Research and Treatment.2019; 51(1): 169. CrossRef
EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand
Mark McKeage, Mark Elwood, Sandar Tin Tin, Prashannata Khwaounjoo, Phyu Aye, Angie Li, Karen Sheath, Phillip Shepherd, George Laking, Nicola Kingston, Christopher Lewis, Donald Love
Targeted Oncology.2017; 12(5): 663. CrossRef
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study
Baohui Han, Sergei Tjulandin, Koichi Hagiwara, Nicola Normanno, Laksmi Wulandari, Konstantin Laktionov, Achmad Hudoyo, Yong He, Yi-Ping Zhang, Meng-Zhao Wang, Chien Ying Liu, Marianne Ratcliffe, Rose McCormack, Martin Reck
Lung Cancer.2017; 113: 37. CrossRef
The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
Hyungjin Kim, Chang Min Park, Bhumsuk Keam, Sang Joon Park, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jin Mo Goo, Fan Yang
PLOS ONE.2017; 12(11): e0187500. CrossRef
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
Seung-Hoon Beom, Dong-Wan Kim, Sung Hoon Sim, Bhumsuk Keam, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo
Cancer Research and Treatment.2016; 48(1): 88. CrossRef
Evolution of targeted therapies in cancer: opportunities and challenges in the clinic
Sam Santhosh, Prasanna Kumar, Vedam Ramprasad, Amitabha Chaudhuri
Future Oncology.2015; 11(2): 279. CrossRef
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation
Bhumsuk Keam, Soo Jin Lee, Tae Min Kim, Jin Chul Paeng, Se-Hoon Lee, Dong-Wan Kim, Yoon Kyung Jeon, Doo Hyun Chung, Keon Wook Kang, June-Key Chung, Dae Seog Heo
Journal of Thoracic Oncology.2015; 10(8): 1189. CrossRef
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer
Sung Hoon Sim, Bhumsuk Keam, Dong-Wan Kim, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo
Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2135. CrossRef

12,235 View
70 Download
9 Crossref

Case Reports

Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman: Hoon-Kyo Kim, Myeong Im Ahn, Jinyoung Yoo, Chi Hong Kim, Hong-Jun Yang, Byoung Yong Shim; Cancer Res Treat. 2007;39(1):37-39. Published online March 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.1.37

Abstract PDF PubReader ePub

A patient with adenocarcinoma of the lung was treated sequentially using two kinds of EGFR tyrosine kinase inhibitors, gefitinib and erlotinib. The patient was a 73-year-old female who received gefitinib as a second line treatment, which resulted in a partial response with response duration of 6 months. After progression of the disease, the patient received erlotinib, which resulted in partial response again with response duration of 11.5 months. This observation suggests that treatment with erlotinib may be effective in patients who develop progressive disease after a primary treatment with gefitinib following an initial response.

Citations

Citations to this article as recorded by

Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Navneet Singh
World Journal of Clinical Oncology.2014; 5(5): 858. CrossRef
Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma
Sung Chul Hong, Yun Su Sim, Jin Hwa Lee, Yon Ju Ryu, Jung Hyun Chang
Tuberculosis and Respiratory Diseases.2011; 71(4): 286. CrossRef

10,207 View
61 Download
2 Crossref

Gefitinib Trial in a Fanconi's Anemia Patient with Multiple Squamous Cell Carcinomas and Hepatocellular Carcinoma: Hae Sun Jung, Gun-Woo Byun, Kyoung-Eun Lee, Yeung Chul Mun, Seung Hyun Nam, Jung Mi Kwon, Shi Nae Lee, Seock-Ah Im, Chu-Myong Seong, Soon Nam Lee; Cancer Res Treat. 2005;37(6):370-373. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.370

Abstract PDF PubReader ePub

FA (Fanconi's Anemia) is an autosomal recessive disorder that is characterized by pancytopenia with bone marrow hypoplasia, diverse congenital abnormalities and an increased predisposition towards malignancy. The mainstay of the treatment for these cancers has been surgery, because of the hypersensitive reactions of FA patients to DNA cross- linking agents or radiation. Therefore, there has been no effective therapy for advanced squa mous cell carcinoma. We report here on a patient suffering from advanced multiple squamous cell carcinoma and hepatocellular carcinoma along with an FA, and this patient was treated with gefitinib.

Citations

Citations to this article as recorded by

Oral Tongue Cancer in a Patient with Fanconi Anemia: A Case Report and Literature Review
Siyao Deng, Wenjing Ye, Shichuan Zhang, Guiquan Zhu, Peng Zhang, Yanqiong Song, Fanglei Duan, Jinyi Lang, Shun Lu
Cancer Management and Research.2021; Volume 13: 3145. CrossRef
Treatment of Fanconi Anemia–Associated Head and Neck Cancer: Opportunities to Improve Outcomes
Rex H. Lee, Hyunseok Kang, Sue S. Yom, Agata Smogorzewska, Daniel E. Johnson, Jennifer R. Grandis
Clinical Cancer Research.2021; 27(19): 5168. CrossRef
Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
Helena Montanuy, Águeda Martínez-Barriocanal, José Antonio Casado, Llorenç Rovirosa, Maria José Ramírez, Rocío Nieto, Carlos Carrascoso-Rubio, Pau Riera, Alan González, Enrique Lerma, Adriana Lasa, Jordi Carreras-Puigvert, Thomas Helleday, Juan A. Bueren,
Clinical Cancer Research.2020; 26(12): 3044. CrossRef
Angiogenesis in chronic liver disease and its complications
Stephanie Coulon, Femke Heindryckx, Anja Geerts, Christophe Van Steenkiste, Isabelle Colle, Hans Van Vlierberghe
Liver International.2011; 31(2): 146. CrossRef

9,884 View
70 Download
4 Crossref

First
Prev
Page of 1
Next
Last

Search